Hermann Mucke (bioscientist)
|This biographical article relies too much on references to primary sources. (August 2007) (Learn how and when to remove this template message)|
Hermann A. M. Mucke (born 4 September 1955) is an Austrian bioscientist with a peer-review publishing record in the fields of molecular biology, neuropsychiatry, cardiology and ophthalmology, mostly from the perspective of drug development. He is also a management consultant and entrepreneur working and publishing in biopharmaceutical strategic knowledge management, intellectual property management, and life science technology assessment.
Hermann Mucke attended the University of Vienna where he obtained his master and Ph.D. degrees in biochemistry. This earliest plant molecular biology phase of Mucke's work concerned the characterization and partial sequencing of the Cyanophora cyanelle genome, believed to resemble early stages of chloroplast evolution according to the endosymbiotic theory.
Industry research executive
After leaving the university Mucke became executive director of research and development at an Austrian pharmaceutical company. He developed an indirect immunofluorescence assay for the detection of antibodies to the human immunodeficiency virus in human body fluids which was approved under the name Fluorognost(TM) HIV-1 by the U.S. FDA approval on 5 February 1992. A human T-lymphotropic virus antibody test, developed by Mucke's team but never marketed, served to demonstrate the first evidence of retrovirus-like serological reactivity in patients with the myelodysplastic syndrome, a finding that meanwhile has been corroborated on the genomic level.
In 1994 Mucke developed a new research focus in neuropsychiatry, initially with a focus on Alzheimer's disease and related neurodegenerative diseases. He directed an R&D program for galantamine derivatives. Soon thereafter he began to cooperate with various pharmaceutical intelligence providers and publishers in the United States and the United Kingdom, both as an author and as a contributing editor.
Industry advisor and publisher
When in 2000 Mucke resigned his executive function in the pharmaceutical industry to set up his own consulting enterprise, the financial newspaper WirtschaftsBlatt took note of the fact. Since this time he has been an independent scientific advisor to life science companies and a prolific author of market and technology reports. He continues to publish his own original scientific research and commissioned reviews both in commercial and open access peer-review journals. His most recent papers demonstrate a systematic utilization of patent documents as a source of information in science, technology, and market research in the fields of ophthalmology, renal and cardiorespiratory medicine, especially pulmonary hypertension, and endothelin receptor antagonists.
By 2009 Hermann Mucke had authored or co-authored about 50 peer reviewed original research papers and invited reviews, in addition to dozens of drug evaluations. He is also a coinventor on several patent families which concern themselves with the pharmacotherapy of alcohol abuse, nicotine dependence, and depression.
Hermann Mucke is Patent Editor at the Thomson Reuters journal, Current Opinion in Investigational Drugs  and an advisor to the Antiviral Spot of Excellence Vienna (ASPEX). He is frequently interviewed by media covering the pharmaceutical industry, mostly on issues concerning the streamlining of drug development through optimization of clinical trials, new approaches to the clinical trial process, or medical imaging.
- Mucke H, Löffelhardt W, Bohnert HJ. Partial Characterization of the Genome of the "Endosymbiotic" Cyanelles from Cyanophora paradoxa. FEBS Lett. 111(2), 347-352 (1980) PMID 6244191
- Mucke H, Löffelhardt W, Bohnert HJ. Cyanelle Genome Organization. In: Advances in Photosynthesis Research, Vol. IV, pp. 579-582. Ed.: Chr. Sybesma, Lancester 1984. ISBN 90-247-2946-7
- Janssen I, Mucke H, Löffelhardt W and Bohnert HJ. The Central Part of the Cyanelle rDNA Unit of Cyanophora paradoxa: Sequence Comparison with Chloroplasts and Cyanobacteria. Plant Mol. Biol. 9, 479-484 (1987)
- Sullivan MT, Mucke H, Kadey SD, Fang CT, Williams AE. Evaluation of an indirect immunofluorescence assay for the confirmation of HIV-1 antibody in U.S. blood donor sera. J Clin Microbiol 30(9), 2509-2510 (1992) PDF
- List of FDA-approved HIV and hepatitis tests
- Möstl M, Mucke H, Schinkinger M, Haushofer A, Krieger O, Lutz D. Indications for the presence of antibodies cross-reactive with HTLVI/II, but not HIV, in patients with myelodysplastic sndrome. Clin. Immunol. Immunopathol. 65(1), 75-79 (1992) PMID 1395126
- Karlic H, Möstl M, Mucke H, Pavlova B, Pfeilstöcker M, Heinz R. Association of human T-cell leukemia virus and myelodysplastic syndrome in a central European population. Cancer Res. 57(21), 4718-4721 (1997) PMID 9354429
- Matsushita K, Inoue H, Kukita T, et al. High proviral load of human T-lymphotropic virus type I in patients with myelodysplastic syndrome carrying HLA-A26. Leuk Lymphoma. 2006; 47(7): 1400-3 PMID 16923577
- Mucke HAM, Czollner K. SPH-1286, a novel potent inhibitor of brain acetylcholinesterase, can prevent amnesia after acute moderate hypoxia-hypercarbia. J Cerebral Blood Flow and Metabolism 19(Suppl. 1), p. S19 (1999)
- WO/1997/026887 Use of galanthamine in the preparation of novel drugs. Published July 31, 1997 Link to PCT document
- WO/2000/032199. Use of galantamine and galantamine derivatives in the case of acute functional brain damage. Published June 8, 2000 Linkt to PCT document
- Pridun C; Menschen in Bewegung. wirtschaftsblatt online archive article, April 14, 2000. Accessed: 2009-06-15. Archived
- Mucke HAM, Mucke P, Mucke E. International patenting in ophthalmology: An analysis of its structure and relevance for the development of drugs and diagnostics. Clin Ophthalmology 3: 103–109 (2009) Open Access paper Archived
- Mucke HA. New ocular therapeutics: a view from the patenting perspective. IDrugs 10(1):37-41 (2007) PMID 17187313
- Mucke HA. Renal therapeutics: patent highlights January to June 2003. Curr Opin Investig Drugs 4(9): 1048-52 (2003) PMID 14582447
- Mucke HA. Cardiovascular and renal developments: patent highlights January to June 2006. Curr Opin Investig Drugs 7(9): 792-8 (2006) PMID 17002256
- Mucke HA. Pulmonary hypertension: on the way to a manageable disease. Curr Opin Investig Drugs 9(9): 957-62 (2008) PMID 18729002
- Mucke HAM. Sitaxentan for the Oral Treatment of Pulmonary Arterial Hypertension: Benefits from Endothelin Receptor Subtype Selectivity? Clinical Medicine: Therapeutics 1: 111-121 (2009) Open Access paper Archived
- Mucke HA. Small-molecule endothelin receptor antagonists: a review of patenting activity across therapeutic areas. IDrugs 12(6): 366-75 (2009) PMID 19517317
- WO/2002/102388 Active ingredient combination of e.g. galantamine or deoxypeganine and e.g. acamprosate or memantine for treating an addiction such as alcoholism. Published December 27, 2002. Link to PCT document
- WO/2004/014393. Medicament and method for reducing alcohol and/or tobacco consumption. Published Feb. 19, 2004. Link to PCT document
- WO/2003/007966. Active substance combination for medicamentous therapy of nicotine dependency. Published January 30, 2003. Link to PCT document
- WO/2003/053445. Use of desoxypeganine for treating clinical depression. Published July 3, 2002. Link to PCT document
- COID journal website
- ASPEX website
- Borman S: Improving Efficiency. Chemical & Engineering News Special Issue published June 19, 2006. Vol 84(25):56-78 Link to article Archived
- Davies K.: Putting the IT in Clinical Trials. BioIT World Vol. 5 Issue 3, p14. April 14, 2006. Link to article Archived
- May M: Exploratory INDs: A Trial Before the Trials. BioIT World Dec. 17, 2007. Link to article Archived
- Ward J: From Mice to Men: Is Imaging the Magic Pill for Faster Drug Development? ADVANCE for Imaging & Radiation Oncology. February 23, 2005. Link to article Archived